Business Description
Founded in Shanghai in 2015, ImmuneOnco Biopharmaceuticals is a drug development company working on cancer treatments in China and the United States. Its leading drug candidate, IMM01, is currently being tested in multiple clinical trials targeting blood cancers such as multiple myeloma, myelodysplastic syndrome, and Hodgkin lymphoma. The company has a broad pipeline of additional treatments in various stages of testing, addressing both blood cancers and solid tumors, as well as conditions like autoimmune disease and atherosclerosis. ImmuneOnco also works with Instil Bio to co-develop two of its pipeline drugs.
